About Us

Ironshore Pharmaceuticals & Development, Inc. is a pharmaceutical company whose mission is to develop innovative, patient-centric treatment options, utilizing the proprietary DELEXIS® technology to improve the lives of patients and caregivers.

What We Do

Based in Grand Cayman, Ironshore Pharmaceuticals & Development, Inc. is responsible for managing all intellectual property, and directing all research, development and manufacturing activities for its drug candidates. Ironshore Pharmaceuticals & Development, Inc. is a wholly owned subsidiary of Toronto-based Highland Therapeutics Inc.

Ironshore Pharmaceuticals & Development, Inc.

Controlled Release

10 Market Street, Suite 715
Camana Bay, KY1-9006
Cayman Islands


David Lickrish
Chief Executive Officer

Dr. Bev Incledon
Chief Scientific Officer

David Lickrish

David Lickrish is the co-inventor, founding shareholder and Chief Executive Officer of Ironshore Pharmaceuticals & Development, Inc.

Under his leadership, Ironshore has grown from a start-up company, founded in the midst of the financial crisis, to an international pharmaceutical company with a proprietary drug-delivery technology and an FDA-approved product since 2018.

Mr. Lickrish studied Microbiology and Finance at the University of Guelph in Canada. He graduated with Honors and received his Bachelor of Commerce in International Economics and Finance. Mr. Lickrish has been a CFA Charter holder since 2001 and has worked internationally covering the Global Pharmaceutical Industry as Senior Vice President of Equity Research.

Dr. Bev Incledon

Dr. Incledon serves as the Company's Chief Scientific Officer. Dr. Incledon has over 28 years of pharmaceutical industry experience encompassing large and small molecule drug discovery, pre-clinical, clinical, product and manufacturing process development roles as well as new R&D facility start-up, and research on novel drug delivery technology. Dr. Incledon gained these experiences through roles with increasing responsibility at Syntex Inc., Glaxo Wellcome Inc., Eli Lilly and Company and several start up biotech companies. Over his career he has been a contributor to 21 clinical development stage and 8 marketed products.

Dr. Incledon was a Post-Doctoral Fellow at Cornell University, conducting his research in mathematical modelling of chaperonin assisted oxidative refolding pathways. He obtained his PhD degree in Biophysics studying the kinetics of multi-subunit protein association from the University of Guelph.